Volume 30, No 11, Nov 2020

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 30 Issue 11, November 2020: 1046-1048   |  Open Access

LETTERS TO THE EDITOR

A mouse model for SARS-CoV-2 infection by exogenous delivery of hACE2 using alphavirus replicon particles

Ya-Nan Zhang¹ , Xiao-Dan Li^1,2 , Zhe-Rui Zhang¹ , Hong-Qing Zhang¹ , Na Li¹ , Jing Liu¹ , Jia-Qi Li¹ , Hua-Jun Zhang¹ , Ze-Jun Wang³ , Shuo Shen³ , Zheng-Li Shi¹ , Hong-Ping Wei¹ , Zhi-Ming Yuan¹ , Han-Qing Ye^1,* , Bo Zhang^1,*

¹Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei 430071, China
²Hunan Normal University, School of Medicine, Changsha, Hunan 410081, China
³Wuhan Institute of Biological Products Co. Ltd., No. 1 Huangjin Industrial Park Road, Jiangxia District, Wuhan, Hubei 420115, China
These authors contributed equally: Ya-Nan Zhang, Xiao-Dan Li, ZheRui Zhang Correspondence: Han-Qing Ye(yehq@wh.iov.cn)Bo Zhang(zhangbo@wh.iov.cn)

Dear Editor,

Since the outbreak of a novel coronavirus disease (COVID-19) in late 2019, it has spread rapidly and developed into a global pandemic. As of August 12, 2020, more than 215 countries and territories around the world have reported more than 20.5 million confirmed COVID-19 cases with over 745,693 deaths (https://www.worldometers.info/coronavirus/#countries). Such harsh conditions urged scientists across the world to gear up to develop vaccines and antiviral drugs against COVID-19, which also lead to massive requirement for experimental animals.

https://doi.org/10.1038/s41422-020-00405-5

FULL TEXT | PDF

Browse 1072